Correlation Between Kura Oncology and Protagonist Therapeutics

Can any of the company-specific risk be diversified away by investing in both Kura Oncology and Protagonist Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kura Oncology and Protagonist Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Kura Oncology and Protagonist Therapeutics, you can compare the effects of market volatilities on Kura Oncology and Protagonist Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kura Oncology with a short position of Protagonist Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kura Oncology and Protagonist Therapeutics.

Diversification Opportunities for Kura Oncology and Protagonist Therapeutics

-0.42

Correlation Coefficient

Kura Oncology  Protagonist Therapeutics

Very good diversification

The 3 months correlation between Kura and Protagonist is -0.42. Overlapping area represents the amount of risk that can be diversified away by holding Kura Oncology and Protagonist Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protagonist Therapeutics and Kura Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kura Oncology are associated (or correlated) with Protagonist Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protagonist Therapeutics has no effect on the direction of Kura Oncology i.e., Kura Oncology and Protagonist Therapeutics go up and down completely randomly.

Pair Corralation between Kura Oncology and Protagonist Therapeutics

Given the investment horizon of 90 days Kura Oncology is expected to under-perform the Protagonist Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Kura Oncology is 1.99 times less risky than Protagonist Therapeutics. The stock trades about -0.08 of its potential returns per unit of risk. The Protagonist Therapeutics is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  3,851  in Protagonist Therapeutics on December 30, 2024 and sell it today you would earn a total of  1,037  from holding Protagonist Therapeutics or generate 26.93% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Kura Oncology  vs.  Protagonist Therapeutics

Kura Oncology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Kura Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Protagonist Therapeutics

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Protagonist Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady technical and fundamental indicators, Protagonist Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Kura Oncology and Protagonist Therapeutics

The main advantage of trading using opposite Kura Oncology and Protagonist Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kura Oncology position performs unexpectedly, Protagonist Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protagonist Therapeutics will offset losses from the drop in Protagonist Therapeutics' long position.

The idea behind Kura Oncology and Protagonist Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.